Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following the exercise of stock options, 170,300 new common shares will be issued and additionally listed on October 29, 2024.
📊 [Key Disclosure Details & Financial Highlights]
- Company Name & Ticker: ALTEOGEN Inc. (A196170)
- Type and Number of Additional Shares: 170,300 Common Shares
- Par Value Per Share: KRW 500
- Total Listed Shares After Additional Listing: 53,318,828 Common Shares
- Listing Date: 2024-10-29
- Dividend Accrual Date: 2024-01-01
- Detailed Issuance Breakdown (Total 170,300 shares / Issuance Date: 2024-10-16):
- 101st Tranche: 21,200 shares (Exercise Price: KRW 10,000)
- 102nd Tranche: 60,000 shares (Exercise Price: KRW 8,917)
- 103rd Tranche: 41,100 shares (Exercise Price: KRW 21,111)
- 104th Tranche: 18,000 shares (Exercise Price: KRW 23,833)
- 105th Tranche: 30,000 shares (Exercise Price: KRW 63,889)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Why Verifying Additional Listing Completion and Share Count Update Is Necessary
This filing is an informational disclosure outlining the schedule and quantity for the additional listing of 170,300 new shares resulting from stock option exercises.
Checking this follow-up item is necessary because the company’s official total outstanding share count is directly updated to 53,318,828 shares starting on the announced listing date (October 29, 2024). Confirming that the additional share listing is successfully completed without discrepancy on the scheduled date and that the official share count is updated accordingly is essential to verify the final execution of the disclosed figures.
The updated share count can be confirmed in upcoming periodic reports or future disclosures on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
